In this file photo from Tuesday, Jan. 27, 2015, a BurgerFi restaurant employee prepares to add cheese to a veggie burger as she grills an order at the Aventura, Fla., restaurant. (AP Photo/Wilfredo Lee)
Plant-based products that do not contain meat can continue to be labeled “sausages” or “burgers,” European lawmakers said Friday, when they rejected a proposal back by the meat industry to ban the terms.
In votes on issues relating to agricultural products, the European Parliament said that so-called veggie burgers, soy steaks and vegan sausages can continue to be sold as such in restaurants and shops across the union.
Europe’s largest farmers' association, Copa-Cogeca, had supported a ban, arguing that labeling vegetarian substitutes with designations bringing meat to mind was misleading for consumers.
On the opposite side of the debate, a group of 13 organizations including Greenpeace and WWF urged lawmakers to reject the proposed amendments, arguing that a ban would have not only exposed the EU “to ridicule," but also damaged its environmental credibility.
They said promoting a shift toward more plant-based diet is in line with the EU Commission's ambition to tackle global warming. Losing the ability to use the terms steak or sausage might make those plant-based products more obscure for consumers.
After the vote, the European Consumer Organization, an umbrella group bringing together consumers' associations, praised the MEPs for their “common sense."
“Consumers are in no way confused by a soy steak or chickpea-based sausage, so long as it is clearly labeled as vegetarian or vegan," the group said in a statement. “Terms such as ‘burger’ or ‘steak’ on plant-based items simply make it much easier for consumers to know how to integrate these products within a meal."
Together with Greenpeace, the group regretted that lawmakers accepted further restrictions on the naming of alternative products containing no dairy. Terms like ‘almond milk’ and ‘soy yogurt’ are already banned in Europe after the bloc's top court ruled in 2017 that purely plant-based products can't be marketed using terms such as milk, butter or cheese, which are reserved for animal products.
Jared Walczak, Vice President of State Projects for the Tax Foundation, joins Cheddar News' Closing Bell, where he explains why a tax exemption for groceries does not benefit lower-income families as much as one would expect. He also makes the argument that a rate cut would actually be more beneficial.
Sourceful is an all-in-one platform for sourcing sustainable materials. The startup recently raised $20 million in a Series A round led by Index Ventures. Through its platform, Sourceful helps businesses find and design more eco-friendly packaging and reduce the carbon footprint of their supply chains. Wing Chan, Co-Founder and CEO of Sourceful, joined Cheddar News' Closing Bell to discuss.
If you did not attend Coachella and spent the weekend scrolling through Tiktok or Instagram, you probably saw a lot influencers comparing Revolve Festival to Fyre Fest.
Content creator Lars Gummer joins Cheddar News to discuss his experience at the festival.
Britt Reichborn-Kjennerud, Section Manager for E-Mobility & Demonstrations for Electric Vehicles, Con Edison and
Joe Morreale, Section Manager of EV Demo Projects and Managed Charging & E-Mobility & Demonstrations, Con Edison, join Cheddar News' Ken Buffa from the New York Auto Show to discuss Con Edison's Clean Energy Commitment and the goal to power New York with 100% clean energy through initiatives like the 'SmartCharge' and 'PowerReady' Programs.
Arthur Madrid, CEO of The Sandbox, and Steven Kolb, CEO of CFDA, join Cheddar News to discuss their partnership focused around fashion in the metaverse.
Ever walk into a CVS to pick up some gum, maybe some Chapstick, only to get hit with a ridiculously long receipt? It’s no secret that most CVS purchases come with these comically long receipts. But what might surprise you is that these long receipts are part of a marketing plan that's paying off big time for CVS.
Johnson & Johnson reported a miss on its Q1 earnings just shy of analyst expectations. The pharmaceutical giant also noted that it has an excess of COVID-19 vaccines and that it will be lowering its end-of-year earnings outlook for 2022.